The test is based on a theory proposed by Dr. Howard Beard and other researchers who contend that cancer is related to a misplaced trophoblast cell that becomes malignant in a manner similar to pregnancy in that they both secrete HCG.
As a consequence, a measure of the amount of HCG found in the blood or urine is also a measure of the degree of malignancy. The higher the number, the greater the severity of the cancer.
Urine, as opposed to blood or serum, is the preferred specimen for the test. In 1980, Papapetrou and co-authors reported the correctness of the urine specimen to be used in HCG Immunoassay. In 32 proven cancer cases, the immunoassay test gave 31 positive results using urine while only 12 positive results were reported using blood. HCG has been found to undergo glycosylation in the liver as it travels in the hepatic circulation. Thus, the HCG molecule cannot be detected. The molecule does not undergo this process in the kidney and therefore the molecule remains intact in the urine.
The test detects the presence of brain cancer as early as 29 months before symptoms appear; 27 months for fibrosarcoma of the abdomen; 24 months for skin cancer; 12 months for cancer of the bones (metastasis from breast cancer extirpated 2 years earlier).
Currently, many cancer patients take advantage of the diagnostic accuracy of this test as an indicator of the effectiveness of their specific mode of therapy. Patients follow a simple direction for preparing a dry extract from the urine sample. The powdery extract is mailed to the Navarro Medical Clinic where the HCG testing is performed.
r
r
No comments:
Post a Comment